Reviewing Thermo Fisher Scientific (NYSE:TMO) and PAVmed (NASDAQ:PAVM)

Thermo Fisher Scientific (NYSE:TMO) and PAVmed (NASDAQ:PAVM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Thermo Fisher Scientific and PAVmed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0	2	18	1	2.95
PAVmed	1	1	1	0	2.00

Thermo Fisher Scientific currently has a consensus price target of $633.68, suggesting a potential upside of 26.30%. PAVmed has a consensus price target of $510.00, suggesting a potential upside of 4,794.43%. Given PAVmed’s higher possible upside, analysts plainly believe PAVmed is more favorable than Thermo Fisher Scientific.

Earnings & Valuation

This table compares Thermo Fisher Scientific and PAVmed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56 billion	4.18	$6.70 billion	$17.74	28.28
PAVmed	$2.99 million	3.42	$39.79 million	($17.12)	-0.61

Thermo Fisher Scientific has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Thermo Fisher Scientific has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Profitability

This table compares Thermo Fisher Scientific and PAVmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.05%	16.92%	8.36%
PAVmed	10,672.42%	-754.98%	-19.87%

Institutional & Insider Ownership

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 5.8% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Thermo Fisher Scientific beats PAVmed on 12 of the 15 factors compared between the two stocks.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.